|Exchange:||NASDAQ national market|
|Stock:||Arena Pharmaceuticals, Inc.|
|Arena Pharmaceuticals, Inc. was incorporated on April 14, 1997, and commenced operations in July 1997. It is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. In June 2012, the US Food and Drug Administration, or FDA, approved its internally discovered drug, BELVIQ, for chronic weight management in adults who are overweight with comorbidity or obese. It focuses on commercializing BELVIQ in the United States and ultimately in additional territories, selectively advancing its drug candidates and discovering additional drug candidates. The Company’s wholly owned subsidiary, Arena Pharmaceuticals GmbH, or Arena GmbH, has provided Eisai Inc., or Eisai, exclusive rights to commercialize BELVIQ in the United States. It have also granted exclusive marketing and distribution rights for BELVIQ to Eisai for rest of North and South America and to Ildong Pharmaceutical Co., Ltd., or Ildong, for South Korea, subject to applicable regulatory approval in each of such territories. Its strategy is to focus on BELVIQ, advance its drug candidates and continue its research and development efforts. The Company competes successfully against these organizations, which include many large, well-financed and experienced pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies. The Company regulates drug products under the Federal Food, Drug, and Cosmetic Act, or FFDCA, and it’s implementing regulations.|
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.